Toshiba Corp. has formed an alliance with the Institute of Human Virology at the University of Maryland Biotechnology Institute over a project directed at optimizing personal medication regimes for AIDS sufferers, it was revealed Thursday.
The project will seek to optimize the efficacy of different regimes to provide AIDS patients with tailor-made therapy, the parties said in a news release.
Patient responses to antiretroviral therapy will be analyzed in relation to the host genetic status gene factors that may influence toxicity and efficacy of the drug, they said.
The project is supported by the state of Maryland and Mitsui Global Strategic Studies Institute, a think tank subsidiary of trader Mitsui & Co., Toshiba and the university added.